Cargando…
Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study
Although transcatheter arterial chemoembolization (TACE) is the standard of care for intermediate-stage hepatocellular carcinoma (HCC), this is a largely heterogeneous disease that includes a subgroup of patients who do not benefit from TACE. The treatment strategy for this subgroup of patients curr...
Autores principales: | Kudo, Masatoshi, Ueshima, Kazuomi, Chan, Stephan, Minami, Tomohiro, Chishina, Hirokazu, Aoki, Tomoko, Takita, Masahiro, Hagiwara, Satoru, Minami, Yasunori, Ida, Hiroshi, Takenaka, Mamoru, Sakurai, Toshiharu, Watanabe, Tomohiro, Morita, Masahiro, Ogawa, Chikara, Wada, Yoshiyuki, Ikeda, Masafumi, Ishii, Hiroshi, Izumi, Namiki, Nishida, Naoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721438/ https://www.ncbi.nlm.nih.gov/pubmed/31370183 http://dx.doi.org/10.3390/cancers11081084 |
Ejemplares similares
-
Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study
por: Ueshima, Kazuomi, et al.
Publicado: (2019) -
Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade
por: Aoki, Tomoko, et al.
Publicado: (2020) -
Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response
por: Minami, Yasunori, et al.
Publicado: (2022) -
Non-Inflamed Tumor Microenvironment and Methylation/Downregulation of Antigen-Presenting Machineries in Cholangiocarcinoma
por: Nishida, Naoshi, et al.
Publicado: (2023) -
Role of β-Catenin Activation in the Tumor Immune Microenvironment and Immunotherapy of Hepatocellular Carcinoma
por: Morita, Masahiro, et al.
Publicado: (2023)